The Prostacyclin Analogue Iloprost Modulates CXCL10 in Systemic Sclerosis. 2022

Tania Colasanti, and Katia Stefanantoni, and Cristina Fantini, and Clarissa Corinaldesi, and Massimiliano Vasile, and Francesco Marampon, and Luigi Di Luigi, and Cristina Antinozzi, and Paolo Sgrò, and Andrea Lenzi, and Valeria Riccieri, and Clara Crescioli
Rheumatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, 155-00161 Rome, Italy.

The prostacyclin analogue iloprost is used to treat vascular alterations and digital ulcers, the early derangements manifesting in systemic sclerosis (SSc), an autoimmune disease leading to skin and organ fibrosis. Bioindicator(s) of SSc onset and progress are still lacking and the therapeutic approach remains a challenge. The T helper 1 (Th1) chemokine interferon (IFN)γ-induced protein 10 (IP-10/CXCL10) associates with disease progression and worse prognosis. Endothelial cells and fibroblasts, under Th1-dominance, release CXCL10, further enhancing SSc's detrimental status. We analyzed the effect of iloprost on CXCL10 in endothelial cells, dermal fibroblasts, and in the serum of SSc patients. Human endothelial cells and dermal fibroblasts activated with IFNγ/Tumor Necrosis Factor (TNF)α, with/without iloprost, were investigated for CXCL10 secretion/expression and for intracellular signaling cascade underlying chemokine release (Signal Transducer and Activator of Transcription 1, STAT1; Nuclear Factor kappa-light-chain-enhancer of activated B cells, NF-kB; c-Jun NH2-terminal kinase, JNK: Phosphatidyl-Inositol 3-kinase (PI3K)/protein kinase B, AKT; Extracellular signal-Regulated Kinase 1/2, ERK1/2). CXCL10 was quantified in sera from 25 patients taking iloprost, satisfying the American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) 2013 classification criteria for SSc, and in sera from 20 SSc sex/age-matched subjects without therapy, previously collected. In human endothelial cells and fibroblasts, iloprost targeted CXCL10, almost preventing IFNγ/TNFα-dependent cascade activation in endothelial cells. In SSc subjects taking iloprost, serum CXCL10 was lower. These in vitro and in vivo data suggest a potential role of iloprost to limit CXCL10 at local vascular/dermal and systemic levels in SSc and warrant further translational research aimed to ameliorate SSc understanding/management.

UI MeSH Term Description Entries
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012595 Scleroderma, Systemic A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA. Sclerosis, Systemic,Systemic Scleroderma,Systemic Sclerosis
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D016285 Iloprost An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation. Ciloprost,Ventavis,ZK-36374,ZK 36374,ZK36374
D042783 Endothelial Cells Highly specialized EPITHELIAL CELLS that line the HEART; BLOOD VESSELS; and lymph vessels, forming the ENDOTHELIUM. They are polygonal in shape and joined together by TIGHT JUNCTIONS. The tight junctions allow for variable permeability to specific macromolecules that are transported across the endothelial layer. Capillary Endothelial Cells,Lymphatic Endothelial Cells,Vascular Endothelial Cells,Capillary Endothelial Cell,Cell, Capillary Endothelial,Cell, Endothelial,Cell, Lymphatic Endothelial,Cell, Vascular Endothelial,Cells, Capillary Endothelial,Cells, Endothelial,Cells, Lymphatic Endothelial,Cells, Vascular Endothelial,Endothelial Cell,Endothelial Cell, Capillary,Endothelial Cell, Lymphatic,Endothelial Cell, Vascular,Endothelial Cells, Capillary,Endothelial Cells, Lymphatic,Endothelial Cells, Vascular,Lymphatic Endothelial Cell,Vascular Endothelial Cell
D054357 Chemokine CXCL10 A CXC chemokine that is induced by GAMMA-INTERFERON and is chemotactic for MONOCYTES and T-LYMPHOCYTES. It has specificity for the CXCR3 RECEPTOR. CXCL10 Chemokine,CXC Chemokine IP-10,Chemokine (C-X-C Motif) Ligand 10,Cytokine IP-10 Protein,IFN-gamma-Inducible Protein, 10 kDa,Interferon-Inducible Protein 10,Interferon-gamma-Inducible Protein of 10 kDa,Small Inducible Cytokine B10,gammaIP-10 Protein,CXC Chemokine IP 10,CXCL10, Chemokine,Chemokine IP-10, CXC,Chemokine, CXCL10,Cytokine IP 10 Protein,IFN gamma Inducible Protein, 10 kDa,IP-10 Protein, Cytokine,Interferon Inducible Protein 10,Interferon gamma Inducible Protein of 10 kDa,gammaIP 10 Protein
D018925 Chemokines Class of pro-inflammatory cytokines that have the ability to attract and activate leukocytes. They can be divided into at least three structural branches: C; (CHEMOKINES, C); CC; (CHEMOKINES, CC); and CXC; (CHEMOKINES, CXC); according to variations in a shared cysteine motif. Chemokine,Chemotactic Cytokine,Chemotactic Cytokines,Cytokines, Chemotactic,Intercrine,Intercrines,Cytokine, Chemotactic

Related Publications

Tania Colasanti, and Katia Stefanantoni, and Cristina Fantini, and Clarissa Corinaldesi, and Massimiliano Vasile, and Francesco Marampon, and Luigi Di Luigi, and Cristina Antinozzi, and Paolo Sgrò, and Andrea Lenzi, and Valeria Riccieri, and Clara Crescioli
January 1988, Annals of the rheumatic diseases,
Tania Colasanti, and Katia Stefanantoni, and Cristina Fantini, and Clarissa Corinaldesi, and Massimiliano Vasile, and Francesco Marampon, and Luigi Di Luigi, and Cristina Antinozzi, and Paolo Sgrò, and Andrea Lenzi, and Valeria Riccieri, and Clara Crescioli
December 2010, BMC immunology,
Tania Colasanti, and Katia Stefanantoni, and Cristina Fantini, and Clarissa Corinaldesi, and Massimiliano Vasile, and Francesco Marampon, and Luigi Di Luigi, and Cristina Antinozzi, and Paolo Sgrò, and Andrea Lenzi, and Valeria Riccieri, and Clara Crescioli
February 1985, Prostaglandins, leukotrienes, and medicine,
Tania Colasanti, and Katia Stefanantoni, and Cristina Fantini, and Clarissa Corinaldesi, and Massimiliano Vasile, and Francesco Marampon, and Luigi Di Luigi, and Cristina Antinozzi, and Paolo Sgrò, and Andrea Lenzi, and Valeria Riccieri, and Clara Crescioli
November 1985, British journal of rheumatology,
Tania Colasanti, and Katia Stefanantoni, and Cristina Fantini, and Clarissa Corinaldesi, and Massimiliano Vasile, and Francesco Marampon, and Luigi Di Luigi, and Cristina Antinozzi, and Paolo Sgrò, and Andrea Lenzi, and Valeria Riccieri, and Clara Crescioli
February 1986, British journal of clinical pharmacology,
Tania Colasanti, and Katia Stefanantoni, and Cristina Fantini, and Clarissa Corinaldesi, and Massimiliano Vasile, and Francesco Marampon, and Luigi Di Luigi, and Cristina Antinozzi, and Paolo Sgrò, and Andrea Lenzi, and Valeria Riccieri, and Clara Crescioli
January 1984, Drug metabolism and disposition: the biological fate of chemicals,
Tania Colasanti, and Katia Stefanantoni, and Cristina Fantini, and Clarissa Corinaldesi, and Massimiliano Vasile, and Francesco Marampon, and Luigi Di Luigi, and Cristina Antinozzi, and Paolo Sgrò, and Andrea Lenzi, and Valeria Riccieri, and Clara Crescioli
August 1990, Thrombosis research,
Tania Colasanti, and Katia Stefanantoni, and Cristina Fantini, and Clarissa Corinaldesi, and Massimiliano Vasile, and Francesco Marampon, and Luigi Di Luigi, and Cristina Antinozzi, and Paolo Sgrò, and Andrea Lenzi, and Valeria Riccieri, and Clara Crescioli
January 1986, European journal of clinical pharmacology,
Tania Colasanti, and Katia Stefanantoni, and Cristina Fantini, and Clarissa Corinaldesi, and Massimiliano Vasile, and Francesco Marampon, and Luigi Di Luigi, and Cristina Antinozzi, and Paolo Sgrò, and Andrea Lenzi, and Valeria Riccieri, and Clara Crescioli
October 1990, European journal of vascular surgery,
Tania Colasanti, and Katia Stefanantoni, and Cristina Fantini, and Clarissa Corinaldesi, and Massimiliano Vasile, and Francesco Marampon, and Luigi Di Luigi, and Cristina Antinozzi, and Paolo Sgrò, and Andrea Lenzi, and Valeria Riccieri, and Clara Crescioli
September 1985, Prostaglandins, leukotrienes, and medicine,
Copied contents to your clipboard!